NewAmsterdam Pharma Company(NAMS)
$20.14+0.17 (+0.85%)
NAMS
NewAmsterdam Pharma Company financials statements
$20.14
At close:+0.17 (+0.85%)
Want to see NAMS full AI Analyst Report?
NewAmsterdam Pharma Company (NAMS) Income Statement
292 Followers
NewAmsterdam Pharma Company Income Statement
Last quarter (Q3 2026), NewAmsterdam Pharma Company's total revenue was $19.16M, an increase of 5406.90% from the same quarter last year. In Q3, NewAmsterdam Pharma Company's net income was $-17.39M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| $ 22.50M | $ 45.56M | $ 14.09M | $ 102.69M | $ 0.00 | |
| $ 22.44M | $ 45.56M | $ 14.09M | $ 102.69M | $ 0.00 | |
| $ 248.13M | $ 221.85M | $ 197.06M | $ 106.25M | $ 34.98M | |
| Depreciation and Amortization | $ 220.00K | $ 113.00K | $ 49.00K | $ 9.00K | $ 5.00K |
| $ -242.32M | $ -241.49M | $ -176.86M | $ -22.34M | $ -41.37M | |
| $ -225.68M | $ -176.29M | $ -182.97M | $ -3.56M | $ -34.98M | |
| $ 21.86M | $ -65.31M | $ 6.06M | $ -19.08M | $ -6.81M | |
| $ -203.82M | $ -241.60M | $ -176.91M | $ -22.63M | $ -41.78M | |
| $ -203.82M | $ -241.60M | $ -176.94M | $ -22.63M | $ -41.78M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.75 | $ -2.56 | $ -2.15 | $ -1.19 | $ -3.34 |
| Diluted EPS | $ -1.75 | $ -2.56 | $ -2.15 | $ -1.19 | $ -3.34 |
| Weighted Average Shares Outstanding | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M |
| Weighted Average Shares Outstanding (Diluted) | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M |
Currency in USD
